Heart Failure
Conditions
Keywords
Heart Failure
Brief summary
A hallmark of patients with heart failure (HF) is premature fatigue which impairs their quality of life and depicts a major source of morbidity. Premature fatigue may be attributed to a) contraction-induced transient changes within muscles (i.e. peripheral fatigue) and/or b) failure of the central nervous system to 'drive' / activate locomotor muscles (i.e. central fatigue). Both determinants of fatigue can lead to a reduction in a muscle's force and power generating capacity and to a compromised ability to perform whole body activities (e.g. walking). Recent findings in health have documented that group III/IV afferent fibers from the working muscle play a critical role in the development of both components of fatigue. Specifically, group III/IV muscle afferents limit central motor drive (CMD) during exercise and thereby exaggerate the development of central fatigue. In contrast, muscle afferents optimize muscle O2 delivery through the precise regulation of circulation and ventilation during exercise and thereby attenuate the development of peripheral fatigue.
Detailed description
Recent findings in HF suggest an altered effect of group III/IV muscle afferents in this population. Although normal afferent feedback is crucial for adequate O2 delivery during exercise, excessive neural feedback has substantial negative consequences. HF patients are characterized by augmented neural feedback arising from overactive muscle afferents. It has been hypothesized that this abnormality compromises locomotor muscle O2 delivery in these patients. Therefore, the abnormally elevated muscle afferent feedback in HF might exacerbate, compared to healthy age- and activity matched individuals (CTRLs), the development of both peripheral (via limiting O2 delivery) and central (via restricting CMD) fatigue during exercise. Recent advances in non-invasive stimulation techniques offer a genuine opportunity to identify the sites and synaptic mechanisms that mediate central and peripheral fatigue including alterations in the responsiveness of the corticospinal tract (i.e. a determinant of central fatigue). Taken together, the proposed studies aim to determine the impact of HF on the precise development of central and peripheral fatigue during both whole body and single muscle exercise and evaluate the extent to which group III/IV muscle afferents contribute to this development.
Interventions
DEVICEElectrical and Magnetic Nerve Stimulators
Stimulation of motor nerve and central nervous system
Mu-opioid receptor agonist
Sponsors
University of Utah
VA Office of Research and Development
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
20 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
* subjects with a history of stable cardiomyopathy (ischemic and non-ischemic, \>1yr duration, ages 20-75 yr), * not pacemaker dependent (no biventricular pacers), * NYHA class II and III symptoms, * Left ventricular ejection fraction (LVEF)\<35%, * no or minimal smoking history (\<15 pk yrs) and on stable medications. * The investigators will also study subjects with preserved ejection fraction * heart failure with a preserved ejection fraction (HFpEF); * LVEF \>50%, * \>1yr duration, * ages 20-75 yr, * not pacemaker dependent, * NYHA class II and III symptoms, * no or minimal smoking history (\<15 pk yrs) and on stable medications. The investigators will exclude morbidly obese patients (BMI \>35), patients with uncontrolled hypertension (\>160/100), anemia (Hgb\<9) and severe renal insufficiency (individuals with creatinine clearance \<30 by the Cockcroft-Gault formula).
Exclusion criteria
* Patients with significant non-cardiac comorbidities, which if present could alter the study results, will be excluded. * Patients will be sedentary, defined here as no regular physical activity for at least the prior 6 months and current activity level will be documented by an activity questionnaire. * Candidates must have no orthopedic limitations that would prohibit them from performing exercise. * Due to the typical age of patients with heart failure, all women will be postmenopausal (either natural or surgical) defined as a cessation of menses for at least 2 years, * and in women without a uterus, follicle stimulating hormone (FSH) \>40 IU/L. * Women currently taking hormone replacement therapy (HRT) will be excluded from the proposed studies due to the direct vascular effects of HRT. * Patients with a pacemaker and / or defibrillator will be excluded from the study due to the use of a magnetic/electric stimulators.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximal Voluntary Quadriceps Force [% Change From Baseline] | 1 minute after exercise on study day | Following dynamic single leg knee extension exercise for a given duration (4-8 min), the decline in maximal voluntary contraction force will be measured. |
| Quadriceps Twitch Force and Voluntary Activation (% Change From Baseline) | During (20 second intervals) and 1 minute after exercise on study day | During a 2-min maximal voluntary quadriceps contraction, central and peripheral fatigue will develop progressively and significantly more in HF vs. CTRLs. |
| Muscle Afferent Affect | 1 minute after exercise on study day | Corticospinal responsiveness will be quantified before and after exercise. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Patients With Heart Failure: Neuromuscular Abnormalities Patients with Heart Failure
Electrical and Magnetic Nerve Stimulators: Stimulation of motor nerve and central nervous system
Intrathecal Fentanyl: Mu-opioid receptor agonist | 16 |
| Health Control Subjects and Neuromuscular Function Health Control Subjects
Electrical and Magnetic Nerve Stimulators: Stimulation of motor nerve and central nervous system
Intrathecal Fentanyl: Mu-opioid receptor agonist | 16 |
| Total | 32 |
Baseline characteristics
| Characteristic | Patients With Heart Failure: Neuromuscular Abnormalities | Health Control Subjects and Neuromuscular Function | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 9 Participants | 8 Participants | 17 Participants |
| Age, Categorical Between 18 and 65 years | 7 Participants | 8 Participants | 15 Participants |
| Age, Continuous | 67 years STANDARD_DEVIATION 3 | 64 years STANDARD_DEVIATION 3 | 66 years STANDARD_DEVIATION 3 |
| Race/Ethnicity, Customized white | 11 Participants | 11 Participants | 22 Participants |
| Region of Enrollment United States | 16 Participants | 16 Participants | 32 Participants |
| Sex: Female, Male Female | 7 Participants | 6 Participants | 13 Participants |
| Sex: Female, Male Male | 9 Participants | 10 Participants | 19 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 0 / 16 | 0 / 16 |
| serious Total, serious adverse events | 0 / 16 | 0 / 16 |
Outcome results
Primary
Maximal Voluntary Quadriceps Force [% Change From Baseline]
Following dynamic single leg knee extension exercise for a given duration (4-8 min), the decline in maximal voluntary contraction force will be measured.
Time frame: 1 minute after exercise on study day
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Patients With Heart Failure: Neuromuscular Abnormalities | Maximal Voluntary Quadriceps Force [% Change From Baseline] | -30 percentage change | Standard Deviation 3 |
| Health Control Subjects and Neuromuscular Function | Maximal Voluntary Quadriceps Force [% Change From Baseline] | -5 percentage change | Standard Deviation 2 |
Primary
Muscle Afferent Affect
Corticospinal responsiveness will be quantified before and after exercise.
Time frame: 1 minute after exercise on study day
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Patients With Heart Failure: Neuromuscular Abnormalities | Muscle Afferent Affect | -30 percent change | Standard Error 3 |
| Health Control Subjects and Neuromuscular Function | Muscle Afferent Affect | 10 percent change | Standard Error 8 |
Primary
Quadriceps Twitch Force and Voluntary Activation (% Change From Baseline)
During a 2-min maximal voluntary quadriceps contraction, central and peripheral fatigue will develop progressively and significantly more in HF vs. CTRLs.
Time frame: During (20 second intervals) and 1 minute after exercise on study day
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Patients With Heart Failure: Neuromuscular Abnormalities | Quadriceps Twitch Force and Voluntary Activation (% Change From Baseline) | Twitch force | -60 percentage change | Standard Deviation 5 |
| Patients With Heart Failure: Neuromuscular Abnormalities | Quadriceps Twitch Force and Voluntary Activation (% Change From Baseline) | Voluntary activation [VA] | -25 percentage change | Standard Deviation 6 |
| Health Control Subjects and Neuromuscular Function | Quadriceps Twitch Force and Voluntary Activation (% Change From Baseline) | Twitch force | -35 percentage change | Standard Deviation 6 |
| Health Control Subjects and Neuromuscular Function | Quadriceps Twitch Force and Voluntary Activation (% Change From Baseline) | Voluntary activation [VA] | -20 percentage change | Standard Deviation 5 |